Abstract There is an urgent need for more effective medications to treat major depressive disorder, as fewer than half of depressed patients achieve full remission and many are not responsive with currently available antidepressant medications or psychotherapy. It is known that prolonged stressful events are an important risk factor for major depressive disorder. However, there are prominent individual variations in response to stress: a relatively small proportion of people (10-20%) experiencing prolonged stress develop stressrelated psychiatric disorders, including depression (susceptibility to stress), whereas most stress-exposed individuals maintain normal psychological functioning (resilience to stress). There have been growing efforts to investigate the neural basis of susceptibility versus resilience to depression. An accumulating body of evidence is revealing the genetic, epigenetic, and neurophysiological mechanisms that underlie stress susceptibility, as well as the active mechanisms that underlie the resilience phenotype. In this review, we discuss, mainly based on our own work, key pathological mechanisms of susceptibility that are identified as potential therapeutic targets for depression treatment. We also review novel mechanisms that promote natural resilience as an alternative strategy to achieve treatment efficacy. These studies are opening new avenues to develop conceptually novel therapeutic strategies for depression treatment.
Introduction
Major depressive disorder (MDD) afflicts 2% to 5% of the population worldwide, ranking first in terms of disability worldwide; and these numbers are continuously increasing [1] [2] [3] [4] [5] [6] . Despite the growing population of depressed patients, fewer than half achieve full remission and many are not responsive with currently available treatments, including antidepressant medications and psychotherapies [2, 3, [5] [6] [7] [8] [9] . One possible reason for this situation is our incomplete understanding of the heterogeneity of the depression syndrome and the wide individual variation seen in response to prolonged or severe stress, an important risk factor for depression. The vast amount of work in this field to date has focused on investigating the pathogenic mechanisms that underlie the development of depression. In contrast, much less attention has been paid to why some individuals are psychophysiologically normal (i.e., resilient to depression), while others are not (i.e., susceptibility to depression) when they experience prolonged stress [2, [10] [11] [12] [13] [14] [15] . There are growing efforts to investigate such differences because understanding the mechanisms that underlie individual variations in Electronic supplementary material The online version of this article (doi:10.1007/s13311-017-0527-x) contains supplementary material, which is available to authorized users. stress responses may have the unique potential to assist in the development of new therapeutic strategies for MDD.
Our group and others have used the chronic social defeat stress (CSDS) model of depression, which allows investigators to segregate susceptible and resilient subpopulations of mice [14, [16] [17] [18] [19] [20] [21] [22] [23] [24] , to explore the molecular and neural mechanisms that underlie the individual variations in response to repeated social stress. Another advantage of the CSDS model is that susceptible mice respond to chronic, not acute, administration of standard antidepressants, as seen in humans. In this review article, we focus mainly on our own work to review several examples of mechanisms of susceptibility or of resilience, both of which provide novel drug targets for future antidepressant drug discovery.
Pathological Mechanisms of Depression Susceptibility
While serendipity has played a leading role in drug discovery efforts for depression and other psychiatric disorders [2, 3] , virtually all rationale approaches until recently have been based on reversing pathogenic mechanisms. With this approach, investigators seek to identify the pathophysiological mechanisms that underlie the persistent maladaptations in an animal's brain that are induced by chronic stress or occur in genetic models of depression.
Rapid Regulation of Depression-Related Behaviors
As noted above, all approved antidepressant medications require several weeks or months of administration to achieve their therapeutic effects. For this reason, research in the field has been based on the notion that the reversal of persistent maladaptations in depressed individuals can only be achieved by chronic treatments. This approach has led to numerous hypotheses for gradual antidepressant responsivity, most notably the neurotrophic hypothesis of depression [25] .
However, more recent work has provided clear evidence that mood status can be regulated rapidly in humans. For instance, Bejjani et al. [26] observed that transient acute depression was induced by high-frequency stimulation of the left subthalamic region of a patient with Parkinson's disease. The effects induced by the stimulation were seen within a time scale of several minutes (Fig. 1) , suggesting unknown, rapidly acting mechanisms that control mood. Shortly thereafter it was discovered that single doses of intravenous ketamine induce rapid antidepressant effects in severely depressed individuals who failed to respond to traditional therapies [27] . This finding has since been replicated in double-blinded studies by several groups [28] , confirming the rapid, bidirectional control of depression.
Consistent with these clinical studies, there is increasing evidence that optogenetically activating or inhibiting selected neural circuits and specific neuronal populations in the brain can rapidly and bidirectionally regulate depression-related behaviors in several rodent models of depression [18, [29] [30] [31] . This work has focused on several reward-and memory-related brain regions, including the medial prefrontal cortex (mPFC), ventral hippocampus (vHIP), nucleus accumbens (NAc), and ventral tegmental area (VTA).
Several studies have reported that the functioning of the mPFC is decreased in both depressed human patients and in animal models of depression. For example, Covington et al. [29] showed that molecular correlates of neuronal activity (i.e., immediate early gene expression) in mPFC were decreased in the postmortem tissues of clinically depressed humans, as well as in mice susceptible to CSDS. Optogenetic stimulation of mPFC neurons during the 5-min social interaction test in depressed susceptible mice rapidly reversed social avoidant behavior and normalized sucrose preference deficits. Similarly, Bagot et al. [32] showed that [26] acute optogenetic stimulation of vHIP glutamatergic nerve terminals that innervate the NAc in the context of submaximal social stress induced social avoidance behavior during the 5-min interaction test, whereas suppression of this specific circuit induced a rapid antidepressant-like response after CSDS.
It was hypothesized many years ago that the mesolimbic dopamine system, composed of the VTA and NAc, is a potential target for rapid antidepressant action [33] . This hypothesis has been consistently supported by more recent optogenetic studies [18] [19] [20] 30] . Chaudhury et al. [18, 19] found that VTA dopamine neurons projecting to the NAc displayed hyperactivity in susceptible mice after CSDS, and that optogenetically mimicking this pathological hyperactivity of VTA-NAc dopamine neurons during the 5-min social interaction test promoted susceptible phenotypes, including social avoidant behavior and decreased sucrose preference (Fig. 2) . In contrast, VTA dopamine neurons projecting to the mPFC exhibit hypoactivity in susceptible mice, and optogenetic inhibition of this VTA-mPFC dopamine circuit also rapidly induces social avoidance, but not decreased sucrose preference [18] . Conversely, suppression of VTA-NAc dopamine neurons, or activation of VTA-mPFC dopamine neurons, exerted proresilience effects. These findings suggest that the VTA-NAc and VTA-mPFC dopamine circuits are functionally different in rapidly inducing depression-related behaviors. Different results were obtained with a different stress model [30] , suggesting further that dopaminergic systems function differently based on the type or severity of the stress involved. Interestingly, Zhang et al. [34] observed that the firing activity of locus coeruleus (LC)-norepinephrine (NE) neurons projecting to the VTA was increased selectively in the resilient mice after CSDS. Optogenetically stimulating these LC-VTA NE neurons has no effect on the social interaction behavior during the 5-min interaction test, but stimulating these neurons 20 min per day for 10 days completely reverses susceptible phenotypes, including social avoidance and decreased sucrose preference. These studies suggest that the acute activation of LC-VTA NE neurons, in contrast to VTA dopamine neurons, has no rapid effect on depressionrelated behaviors.
These studies support the idea that specific integrative synaptic circuits within the brain are capable of mediating rapid effects on depression-related behaviors, either inducing those behaviors or reversing them depending on the circuit and experimental conditions involved. However, more investigations are needed to explore details about the role of individual circuits in acute regulation of mood and in validating these effects in humans. It would also be important to know whether or not these same circuits mediate the rapid antidepressant actions of ketamine.
Brain-Derived Neurotrophic Factor
Brain-derived neurotrophic factor (BDNF) is implicated in playing an important role in the pathophysiology of depression and in mediating antidepressant actions [7, 25, [35] [36] [37] [38] . However, its pathological changes are distinct in different brain regions [7, 39] . In particular, higher levels of BDNF in the mesolimbic dopamine reward circuit are associated with a depression phenotype, which is opposite to the antidepressant- [18] like role for BDNF in the hippocampus [3, 4, 14, 40] . We focus here on the prodepression-like effect of BDNF in the VTA-NAc pathway; the reader is referred elsewhere for a review of BDNF actions in hippocampus [41] .
In the CSDS model of depression, Berton and Nestler [3] reported that CSDS increased the levels of BDNF in the NAc, and showed that the VTA is the crucial source of BDNF for this increase. A later study demonstrated increased BDNF levels in NAc of susceptible but not resilient mice [14] . This BNDF change is coincident with the increase in the firing activity of VTA dopamine neurons seen in susceptible mice only (see more information below). Cao et al. [17] showed that the baseline firing rate and phasic firing properties of VTA dopamine neurons in anesthetized mice were increased selectively in susceptible mice. Interestingly, optogenetic phasic but not tonic stimulation of VTA-NAc dopamine neurons during the social interaction test induced social avoidance behavior and a sucrose preference deficit in mice exposed to submaximal social defeat stress [18] . Consistent with these behavioral data, optogenetic phasic activation of VTA-NAc dopamine neurons after such submaximal social stress induced a dramatic increase in BDNF levels in NAc, whereas tonic stimulation of these neurons was without effect [19] .
Importantly, we showed recently that intra-NAc infusion of a BDNF-tyrosine receptor kinase B (TrkB) antagonist, but not dopamine receptor antagonists, prevented CSDS-induced behavioral abnormalities [31] . Local knockout of BDNF from the VTA had a similar effect. Moreover, repeated optogenetic phasic stimulation of the VTA-NAc circuit exacerbated the social defeat-induced behavioral symptoms, effects that were normalized by intra-NAc infusion of a TrkB antagonist. These findings support the view that BDNF-TrkB signaling, rather than dopamine signaling, in the VTA-NAc circuit mediates CSDS-induced depressive-like behaviors. As BDNF exerts opposite effects in different neural circuits, targeting BDNFTrkB signaling may not be the most advantageous approach for drug discovery efforts. Rather, current work is focused on identifying signaling proteins downstream of BDNF-TrkB, which might be targeted for novel therapeutics.
Corticotrophin Releasing Factor
Corticotrophin releasing factor (CRF) has long been of interest in depression research as an upstream regulator of the hypothalamic-pituitary-adrenal axis. More recent research has implicated a role for CRF in the VTA-NAc reward circuit. It is known that mesolimbic dopamine neurons respond to rewarding, as well as aversive, stimuli, and can mediate divergent behavioral outputs [14, 17, 30, [42] [43] [44] [45] . This suggests a possible context-specific role of this mesolimbic circuit in encoding behaviors. Walsh et al. [19] replicated that optogenetic phasic stimulation of VTA-NAc dopamine neurons, in the context of submaximal social defeat stress, induced social avoidant behavior, as stated above. However, the same optogenetic stimulation of these neurons in stressnaïve mice had no effect on social interaction behavior or on NAc BDNF levels, suggesting that phasic stimulation alone is not sufficient to induce BDNF release and its behavioral sequelae.
In further work, Walsh et al. [19] demonstrated that the intra-NAc infusion of a CRF receptor antagonist blocked the phasic stimulation-induced social avoidance in mice that were subjected to submaximal defeat. In contrast, in stress-naïve mice, the combination of intra-NAc infusion of CRF plus phasic stimulation of VTA-NAc dopamine neurons increased NAc BDNF levels without affecting social behavior. These findings support the notion that CRF acting in the NAc gates the ability of phasic firing, in the context of stress, to increase BDNF signaling in the NAc and that such increased BDNF signaling promotes depression-like behavioral abnormalities but only in conjunction with other stress-induced maladaptations.
Chromatin Mechanisms of Stress Susceptibility
We have proposed that the persisting nature of behavioral abnormalities induced by CSDS and other forms of chronic stress in animal models, and by analogy in depressed patients, is mediated, in large part, through lasting changes in gene expression [46] . A corollary of this hypothesis is that such lasting changes in gene expression are mediated by stable chromatin modifications that control gene transcription. While this work remains at relatively early stages of development, growing empirical evidence supports the importance of chromatin abnormalities as key pathophysiological mechanisms of depression.
Histone deacetylases (HDACs) remove acetyl groups from several Lys residues in histone proteins, which generally promote gene expression. Open-ended, genome-wide explorations of gene expression in several brain regions have shown-surprisingly-that fewer genes are altered by CSDS in susceptible versus resilient mice [14, 24] , suggesting that susceptibility may represent the failure of plasticity due to mechanisms that suppress transcriptional regulation. In support of this possibility, the direct infusion of HDAC inhibitors into any of several brain regions, including the mPFC, vHIP, NAc, or amygdala, exert antidepressant-like effects [47] [48] [49] . In some brain regions, HDAC inhibition was more effective than standard antidepressant therapy. Systemic administration of such inhibitors are only weakly effective [37, 50] , but this is likely due to the poor penetration of available inhibitors into the brain. The robust efficacy of HDAC inhibitors in animal models supports the value in developing more selective inhibitors that penetrate the brain.
Another mechanism that contributes to the loss of transcriptional plasticity in depression is stress induction of BAZ1A, a chromatin remodeling factor that suppresses gene expression [51] . BAZ1A is induced in the NAc of depressed humans and chronically stressed mice, an effect seen in both males and females. Overexpression of BAZ1A in NAc of mouse models promotes stress susceptibility, whereas its knockdown in this brain region promotes resilience and also reverses depression-related behavioral abnormalities induced by CSDS. While drugs that inhibit BAZ1A directly are likely to be too broadly acting to be safe in treating depression, targeting the specific genes that are suppressed by BAZ1A in the depressed state would be a viable path for antidepressant discovery efforts.
Chromatin mechanisms are highly complex and it would be a mistake to view all suppressive mechanisms as prodepressant. An example of this complexity is G9a, a histone methyltransferase that methylates certain Lys residues on the histone H3 subunit, a modification that promotes suppression of gene expression. Levels of G9a and its methylated histone mark are reduced in NAc of depressed humans and chronically stressed mice [52] . Local knockdown of G9a in this brain region promotes susceptibility in stressed mice, whereas overexpression of G9a causes the opposite effect. Interestingly, one of the major pathways affected by G9a and its histone-methylating effects is BDNF-TrkB signaling: loss of G9a in NAc in the depressed state leads to increased expression levels of proteins downstream of TrkB, which ultimately lead to increased activation of the transcription factor, cAMP response element binding protein [52] . cAMP response element binding protein, like BDNF, exerts different effects on depression-related abnormalities, promoting depression in NAc but opposing depression in hippocampus [7] .
A New Therapeutic Strategy: Targeting Mechanisms of Resilience
According to the American Psychological Association (2014), resilience is defined as Bthe process of adapting well in the face of adversity, trauma, tragedy, threats or even significant sources of stress^. Increasing evidence supports the view that promoting mechanisms of natural resilience represents a bone fide alternative path for generating novel antidepressant treatments.
Active Resilience
It has become clear that resilience is an active stress-coping mechanism, rather than a simple lack of pathological alterations in response to prolonged adverse stimuli. Many psychosocial coping skills, including facing fears, optimism, cognitive reappraisal, and purpose of life, have long been used successfully in daily life [53] . Recent studies have begun to reveal the neurobiological basis for resilience mechanisms [54, 55] . Active coping behaviors, such as escape and aggression, are associated with more transient activation of the hypothalamus-pituitary-adrenal axis [56] . Consistent with this, overexpression of CRF in mutant mice increases active coping behavior, a phenomenon that is mediated partly by enhanced noradrenergic activity [57] . In contrast, positive emotions and mutual cooperation are linked to the function of the mesolimbic reward neural circuit [58] .
Studies with the CSDS model are consistent with this view of active resilience. As noted above, genome-wide measures of gene expression changes show greater plasticity in most brain regions of resilient mice as compared with susceptible mice; this is illustrated for the VTA and NAc in Fig. 3 . Additionally, the firing rate and bursting events of VTA dopamine neurons-as assessed in both in vitro brain slice work and in vivo electrophysiological studies-is increased in susceptible mice, but not in the resilient subgroup as discussed earlier [14, 17] . Subsequent work demonstrated that the ability of resilient mice to escape this pathological maladaptation is based on their ability to mount additional mechanisms of plasticity that normalize VTA function. These observations establish the VTA as a useful model system in which to understand molecular and cellular mechanisms of active resilience.
KCNQ Potassium Channels as Novel Drug Targets
VTA dopamine neurons respond differentially to distinct stressors [30, [59] [60] [61] [62] [63] . Studies from several groups showed that CSDS induces a hyperactivity of VTA dopamine neurons in susceptible mice [14, 17, 20, [60] [61] [62] 64] . Moreover, VTA dopamine neurons are heterogeneous with respect to their projection pathways. As stated earlier, in susceptible mice, VTA-NAc dopamine neurons display hyperactivity, whereas VTA-mPFC dopamine neurons exhibit decreased firing. In contrast to susceptible mice, the resilient group has a control-level firing activity in both of these projection circuits [18] [19] [20] .
Mechanistically, in susceptible mice, the VTA-NAc dopamine neurons display an increased excitatory I h current (hyperpolarization-activated cation channel current), which drives the pathological hyperactivity of these neurons [17, 20] . Unexpectedly, in the resilient group, the VTA-NAc dopamine neurons have an even larger excitatory I h current, which is observed in parallel with increased inhibitory K + channel currents. This finding suggests that a homeostatic E/I current balance stabilizes the firing activity and maintains decreased excitability of VTA-NAc dopamine cells in the resilient phenotype [20, 55, 65] (Fig. 4) . This neurophysiological work demonstrates that resilience uses more ion channelmediated currents to cope actively with stress, which is consistent with previous molecular studies showing more genes regulated in the resilient group [14, 24, 54] . In particular, there are 4 different subtypes of K + channels, including KCNQ channels, selectively upregulated in the VTA of resilient mice [14] . This insight into the molecular and cellular basis of natural resilience as an active stress-coping process offers a new therapeutic direction. Friedman et al. [20] demonstrated that KCNQ channel function was significantly upregulated in the VTA-NAc dopamine neurons of resilient mice, with no effect seen in susceptible mice. KCNQ overexpression in these neurons of the susceptible subgroup normalized their pathologic neuronal hyperactivity and reversed the animals' depressionlike behavioral abnormalities. Furthermore, KCNQ Bopeners( potentiators), applied through either local infusion into the VTA or systemic administration, completely reversed the depressive-like symptoms displayed by susceptible animals. Ezogabine (retigabine) is a nonselective KCNQ potentiator and is approved by the approved for the treatment of epilepsy. Systemically administrated ezogabine normalized both VTA neuronal hyperactivity and depression-like behaviors seen in susceptible mice [21] . These findings provided the rationale for a small scale clinical trial of ezogabine in treatmentresistant depressed patients who exhibit prominent anhedonia symptoms and reduced functional magnetic resonance imaging signals in the NAc. Ezogabine reversed both of these abnormalities [66] , thus setting the stage for a larger clinical trial now underway. Together, this work identifies KCNQ as a target for conceptually novel antidepressants that function through the potentiation of active resilience mechanisms. Moving forward it would be important to generate more selective KCNQ potentiators that target channel subtypes enriched in VTA. Fig. 3 Resilience is an active process of adapting to adverse stimuli, rather than a passive lack of maladaptations. a Microarray data show that > 300 and 80 genes are regulated in nucleus accumbens (NAc) and ventral tetmental area (VTA), respectively, of susceptible mice, as compared with stress-naïve handled controls. By contrast, many more genes (482 in the NAc and 171 in the VTA) are regulated in the resilient (unsusceptible) subpopulation. b Heat maps illustrate the regulation of genes in the NAc and VTA of susceptible and resilient mice, with red-to-blue gradient depicting an upregulation to downregulation (≥2-fold increase → ≤2-fold decrease). In each panel, top and bottom rows show significantly regulated genes in susceptible and resilient mice, respectively. Adapted from Krishnan et al., [14] 
NE Mechanisms of Resilience
Emerging evidence implicates the LC-NE system in stress resilience [67] [68] [69] . It is well known that the LC-NE nucleus responds to stress by Bpriming^neurons throughout the brain [68, [70] [71] [72] [73] [74] [75] [76] . For instance, in response to acute stress, the LC-NE system shifts the brain into a rapid defense-mechanism state [77] . An increasing number of studies has also demonstrated the heterogeneous principles of organization and operation of LC-NE neurons, as seen in the VTA dopaminergic system. Previous evidence showed that LC neurons innervate the VTA [78] [79] [80] .
Consistent with these early studies, Zhang et al. [34] found recently that, in the CSDS paradigm, resilient mice displayed an increased firing activity of LC neurons that project to the VTA, and that repeated optogenetic activation of LC-VTA NE neurons (20 min per day for 10 days) in susceptible mice reversed depression-like behaviors and pathological hyperactivity of VTA-NAc dopamine neurons as stated above. Utilizing a circuit-mapping molecular profiling technique, this study screened the molecular targets of LC noradrenergic inputs onto VTA-NAc dopamine neurons and found a higher expression of α1b and β3 adrenoceptors in VTA-NAc dopamine neurons. Further investigation revealed that repeated intra-VTA infusion of α1 and β3 agonists for 10 days normalized social avoidance behavior and pathological hyperactivity of VTA-NAc dopamine neurons, which is consistent with the 10-day optical stimulation-induced effects [34] . Consistent with these findings, Isingrini et al. [81] reported that elevated NE release was observed in the VTA of resilient animals. These highly consistent findings implicate the potential role of NE in mediating resilience mechanisms in the VTA.
Current research is focusing on further characterizing the NE receptor(s) that mediate these proresilience actions, with the notion that agonists at those receptors might represent another approach for antidepressant therapy.
Transcriptional Mechanisms of Resilience
There have also been efforts to identify the transcription factors that drive the considerable degree of transcriptional plasticity that occurs throughout the brain in resilient animals. One of the best characterized is ΔFosB, a truncated product of the FosB immediate early gene. ΔFosB is unique among immediate early gene products in that it is a stable protein, which accumulates in a region-specific manner in brain in response to many types of chronic perturbations and thereby mediates lasting transcriptional effects [82] . ΔFosB is most studied in drug abuse models, where its induction in NAc in response to chronic drug administration promotes drug reward and a drugaddicted state. More recent research has demonstrated the importance of ΔFosB in stress models as well [83] . ΔFosB is induced selectively in D1-type medium spiny neurons of the NAc in resilient mice after CSDS, where its overexpression has been shown to promote resilience and prevention of its induction promoted susceptibility [84, 85] . Such induction of ΔFosB in the NAc of resilient animals is mediated by another transcription factor, serum response factor, which also promoted resilience in this brain region [86] .
Another proresilient transcription factor is β-catenin, which is downstream of WNT signaling and implicated in numerous cellular functions. WNT signaling pathways are among the most highly regulated in the NAc of resilient animals after CSDS based on genome-wide studies of gene Fig. 4 Active ion-channel mechanisms that underlie resilience. a I h sample traces and statistical data for control (open circles), susceptible (filled black squares), and resilient (filled gray triangles) mice. Post hoc analysis at -130 mV shows a significant increase in I h in susceptible mice and an even significantly larger I h increase in the resilient subgroup compared with the control. b Sample traces and statistical data of isolated K + channel-mediated currents recorded from VTA dopamine neurons show that resilient mice have significantly increased peak and sustained phases of K + currents. Post hoc analysis shows a slight increase in peak K + currents in susceptible mice and a larger increase in the resilient subgroup compared with the controls. c Susceptible mice display increased dopamine neuron excitability, whereas resilient mice display a reduction, after incremental steps in current injections (50, 100, 150, and 200 pA), compared with controls. Post hoc analysis of susceptible and resilient compared with control mice for 100, 150, and 200 pA currents at p < 0.05. Adapted from Friedman et al. [20] expression [87] . This action appears to be selective for D2-type medium spiny neurons [22] . Consistent with these findings, overexpression of β-catenin in D2 neurons of NAc promoted resilience, whereas its knockdown in this region promoted susceptibility [22] .
A major challenge of this research is how to translate these results into the clinic. Transcription factors are not common drug targets for psychiatric syndromes, although they are increasingly targeted in other fields of medicine (e.g., cancer). It is also argued that drugs that target transcription factors have the additional impediment of having to penetrate the cell and nucleus; however, most drugs that penetrate the blood-brain barrier also penetrate cell and nuclear membranes. A more compelling obstacle is that most transcription factors are broadly expressed, such that drugs that target them are likely to cause many off-target effects. This is particularly the case for β-catenin, which is expressed ubiquitously and whose activation systemically would be expected to cause cancer. For this reason, many transcription factors should not be viewed as drug targets themselves, but as ways of identifying the key genes through which they produce their behavioral effects, with the products of those genes representing bona fide drug targets. For example, we and others have mapped transcription factor targets in the brain by use of chromatin immunoprecipitation followed by deep sequencing (ChIPseq) (e.g., [22] ). The results of this study revealed numerous gene targets whose protein products could conceivably serve as the basis for future drug discovery efforts.
Nevertheless, ΔFosB may be an exception to the notion that transcription factors are not easily druggable. It is not expressed broadly in the brain or periphery such that drugs that directly target ΔFosB might be viable therapeutically. Nevertheless, a final challenge with this approach is the diversity of ΔFosB actions in different neuronal cell types. While ΔFosB exerts proresilient and antidepressant-like effects when activated in D1 NAc neurons, it does the opposite when activated in D2 NAc neurons [85] . It also does the opposite when induced in mPFC pyramidal neurons [88] . Therefore, the only way to assess the therapeutic potential of ΔFosB is to develop tool compounds that can be given systemically and either inhibit or activate ΔFosB. The lack of availability of such tool compounds to ΔFosB and a range of other novel targets is one of the greatest hurdles in central nervous system drug discovery.
Conclusion
The enormous impact of depression on humanity, and limitations in currently available therapies, make it imperative to develop more effective treatments for this syndrome. Most work in the field over several decades has focused on ways to reverse the deleterious effects of chronic stress in animal models. This remains, of course, a viable approach, even though we have, to date, failed to introduce antidepressants with novel mechanisms of action. One explanation for this failure is that many of the adaptations that occur in genetically normal animals in response to chronic stress do not mediate the deleterious effects of the stress, but rather represent adaptive mechanisms that serve to help the individual cope positively with the stress. A crucial innovation in recent years is the ability to distinguish between susceptible versus resilient animals subjected to chronic stress. Antidepressant drug discovery efforts will thus be helped moving forward by efforts to reverse mechanisms demonstrated specifically to promote susceptibility. Additionally, another innovation is to understand mechanisms of natural resilience with the novel idea that promoting such mechanisms in more susceptible individuals represents a novel path for antidepressant drug discovery. Indeed, in recent years, many new genetic, epigenetic and neurophysiological mechanisms of stress susceptibility and resilience have been revealed and validated in animal models, with several now being tested in the clinic. We remain hopeful that these new avenues offer conceptually original therapeutic strategies for depression treatment.
